 "Aurobindo Pharma hits new high on robust Q2 results")
Aurobindo Pharma is trading higher by 3% at Rs 1,032 on NSE after reporting a robust 58% year on year (yoy) jump in consolidated net profit at Rs 372 crore for the second quarter ended September 2014 (Q2), mainly on account of overall growth led by US Generics. The drug maker had profit of Rs 235 crore in a year ago quarter.
Consolidated net operating income in July-September quarter grew by 50% to Rs 2,881 crore against Rs 1,914 crore in the corresponding quarter of previous fiscal.
EBITDA or operating profit margin however, declined to 22.1% from 22.9% during the recently concluded quarter.
“The EBITDA during the quarter on Y-o-Y basis has declined by 79bps due to increase in staff cost and other expenses to net operating income by 1.5% and 3.4% respectively, offset by decrease in materials consumptions to net operating income by 4.1% as a result of improved business mix,” Aurobindo Pharma said in a statement.
The stock opened at Rs 1,002 and hit a new high of Rs 1,039 on NSE. A combined 1.7 million shares changed hands on the counter till 1050 hours on NSE and BSE.
Consolidated net operating income in July-September quarter grew by 50% to Rs 2,881 crore against Rs 1,914 crore in the corresponding quarter of previous fiscal.
EBITDA or operating profit margin however, declined to 22.1% from 22.9% during the recently concluded quarter.
“The EBITDA during the quarter on Y-o-Y basis has declined by 79bps due to increase in staff cost and other expenses to net operating income by 1.5% and 3.4% respectively, offset by decrease in materials consumptions to net operating income by 4.1% as a result of improved business mix,” Aurobindo Pharma said in a statement.
The stock opened at Rs 1,002 and hit a new high of Rs 1,039 on NSE. A combined 1.7 million shares changed hands on the counter till 1050 hours on NSE and BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%